2016 classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a European League Against Rheumatism/American …
Objective To develop criteria for the classification of macrophage activation syndrome (MAS)
in patients with systemic juvenile idiopathic arthritis (JIA). Methods A multistep process …
in patients with systemic juvenile idiopathic arthritis (JIA). Methods A multistep process …
Loss-of-function variant in DNASE1L3 causes a familial form of systemic lupus erythematosus
SM Al-Mayouf, A Sunker, R Abdwani, SA Abrawi… - Nature …, 2011 - nature.com
Systemic lupus erythematosus (SLE) is a complex autoimmune disease that causes
substantial morbidity. As is typical for many other multifactorial disorders, much of the …
substantial morbidity. As is typical for many other multifactorial disorders, much of the …
[HTML][HTML] Epidemiology and demographics of juvenile idiopathic arthritis in Africa and Middle East
SM Al-Mayouf, M Al Mutairi, K Bouayed… - Pediatric …, 2021 - Springer
Abstract Juvenile Idiopathic Arthritis (JIA) is a group of chronic heterogenous disorders that
manifests as joint inflammation in patients aged< 16 years. Globally, approximately 3 million …
manifests as joint inflammation in patients aged< 16 years. Globally, approximately 3 million …
[HTML][HTML] The landscape of genetic diseases in Saudi Arabia based on the first 1000 diagnostic panels and exomes
D Monies, M Abouelhoda, M AlSayed, Z Alhassnan… - Human genetics, 2017 - Springer
In this study, we report the experience of the only reference clinical next-generation
sequencing lab in Saudi Arabia with the first 1000 families who span a wide-range of …
sequencing lab in Saudi Arabia with the first 1000 families who span a wide-range of …
Treating juvenile idiopathic arthritis to target: recommendations of an international task force
Recent therapeutic advances in juvenile idiopathic arthritis (JIA) have made remission an
achievable goal for most patients. Reaching this target leads to improved outcomes. The …
achievable goal for most patients. Reaching this target leads to improved outcomes. The …
Phenotypic and genotypic characteristics of cryopyrin-associated periodic syndrome: a series of 136 patients from the Eurofever Registry
R Levy, L Gérard, J Kuemmerle-Deschner… - Annals of the …, 2015 - ard.bmj.com
Objective To evaluate genetic, demographic and clinical features in patients with cryopyrin-
associated periodic syndrome (CAPS) from the Eurofever Registry, with a focus on genotype …
associated periodic syndrome (CAPS) from the Eurofever Registry, with a focus on genotype …
Systemic sclerosis in childhood: clinical and immunologic features of 153 patients in an international database
G Martini, I Foeldvari, R Russo, R Cuttica… - … : Official Journal of …, 2006 - Wiley Online Library
Objective To determine the clinical and immunologic features of systemic sclerosis (SSc) in
a large group of children and describe the clinical evolution of the disease and compare it …
a large group of children and describe the clinical evolution of the disease and compare it …
Phenotypic variability and disparities in treatment and outcomes of childhood arthritis throughout the world: an observational cohort study
A Consolaro, G Giancane, A Alongi… - The Lancet Child & …, 2019 - thelancet.com
Background To our knowledge, the characteristics and burden of childhood arthritis have
never been studied on a worldwide basis. We aimed to investigate, with a cross-sectional …
never been studied on a worldwide basis. We aimed to investigate, with a cross-sectional …
Results from a multicentre international registry of familial Mediterranean fever: impact of environment on the expression of a monogenic disease in children
S Ozen, E Demirkaya, G Amaryan… - Annals of the …, 2014 - ard.bmj.com
Background and aim Familial Mediterranean fever (FMF) is an autoinflammatory disease
caused by mutations of the MEFV gene. We analyse the impact of ethnic, environmental and …
caused by mutations of the MEFV gene. We analyse the impact of ethnic, environmental and …
Intravenous immunoglobulin therapy for juvenile dermatomyositis: efficacy and safety.
SM Al-Mayouf, RM Laxer, R Schneider… - The Journal of …, 2000 - europepmc.org
Objective To assess the efficacy of intravenous immunoglobulin (IVIG) for the treatment of
juvenile dermatomyositis (JDM) in patients who were unresponsive to corticosteroids …
juvenile dermatomyositis (JDM) in patients who were unresponsive to corticosteroids …